/

Batteries & E-Mobility

/

Loxo@Lilly

Loxo@Lilly

Loxo@Lilly

Verified Nov 2026

Batteries & E-Mobility

·

United States flag

Stamford, Connecticut

·

Since 2013

Loxo@Lilly is a biopharmaceutical subsidiary of Eli Lilly and Company headquartered in Stamford, Connecticut. Founded in 2013 and acquired by Lilly in 2019, the company develops precision-targeted oncology medicines for patients with genomically defined cancers. With 500 to 1,000 employees and estimated annual revenue between $100 million and $250 million, it operates as Lilly's global precision oncology unit. The company has brought approved therapies to market, including treatments for NTRK fusion-positive and RET-mutant cancers.

Loxo@Lilly

Verified Nov 2026

AT A GLANCE

Founded

2013

Headquarters

United States flag

Stamford, Connecticut

Employees

500-1,000

Ownership

Loxo@Lilly at a glance

Revenue

$100-250M

Est. band

Employees

500-1,000

Founded

2013

Headquarters

Stamford, Connecticut

Industries

Automotive

Electric Vehicles

Medical

Overview

Loxo@Lilly is a biopharmaceutical subsidiary of Eli Lilly and Company headquartered in Stamford, Connecticut. Founded in 2013 and acquired by Lilly in 2019, the company develops precision-targeted oncology medicines for patients with genomically defined cancers. With 500 to 1,000 employees and estimated annual revenue between $100 million and $250 million, it operates as Lilly's global precision oncology unit. The company has brought approved therapies to market, including treatments for NTRK fusion-positive and RET-mutant cancers.

At a glance

Attribute

Detail

Founded

2013

Headquarters

Stamford, Connecticut

Employees

500-1,000

Revenue

$100-250M (estimated)

Primary capability

Batteries & E-Mobility

What Loxo@Lilly makes

Loxo@Lilly specializes in discovery and development of targeted therapies, accelerated clinical trial execution, and precision medicine strategies that address unmet oncology needs in patients with specific gene abnormalities.

Company details

As a subsidiary of Eli Lilly and Company, the company combines a biotech operational model with the resources and infrastructure of a major global pharmaceutical corporation. Loxo@Lilly was founded in 2013, has an estimated 500-1,000 employees, and is headquartered in Stamford, Connecticut.

Frequently asked questions

What does Loxo@Lilly make?

Loxo@Lilly is a biopharmaceutical subsidiary of Eli Lilly and Company headquartered in Stamford, Connecticut. Founded in 2013 and acquired by Lilly in 2019, the company develops precision-targeted oncology medicines for patients with genomically defined cancers. With 500 to 1,000 employees and estimated annual revenue between $100 million and $250 million, it operates as Lilly's global precision oncology unit. The company has brought approved therapies to market, including treatments for NTRK fusion-positive and RET-mutant cancers.

Where is Loxo@Lilly headquartered?

Loxo@Lilly is headquartered in Stamford, Connecticut (281 Tresser Boulevard, Stamford, Connecticut, 06901).

When was Loxo@Lilly founded?

Loxo@Lilly was founded in 2013.

How big is Loxo@Lilly?

Loxo@Lilly has an estimated 500-1,000 employees, with revenue in the $100-250M range (estimated).

Related suppliers

Explore other suppliers in the LightSource directory:

Last verified Nov 2026. Is this your company? Request a correction.

Location & contact

Stamford, Connecticut (HQ)Headquarters · United States
Stamford, Connecticut (HQ)281 Tresser Boulevard, Stamford, Connecticut, 06901, United StatesHeadquarters

Evaluating suppliers like these?

This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.